Person: Soriot

A COMPREHENSIVE SERIES OF ARTICLES ON THIS TOPIC

Drug firm in €3.5bn drop

Shares in AstraZeneca fell more than 5%, stripping at one stage €3.5bn from its market value, after the drug company declined to deny a media report that chief executive Pascal Soriot was about to defect to Israel-based Teva Pharmaceutical.

Fri, 14 Jul, 2017

AstraZeneca chases $5bn Acerta Pharma deal for better cancer drug portfolio

AstraZeneca said yesterday it was in talks that might lead to the acquisition of privately held biotech firm Acerta Pharma, a potential $5bn-plus (€4.54bn) deal designed to build up its cancer drug portfolio.

Tue, 15 Dec, 2015

AstraZeneca strikes $700m deal with Dublin-based Actavis

Drugs giant AstraZeneca is to boost its portfolio with the acquisition of a branded respiratory drug business for up to US $700m (€613m).

Thu, 05 Feb, 2015

AstraZeneca results show firm’s strength

AstraZeneca, which saw off a €95bn bid from Pfizer in May, said quarterly results showed its stand-alone strength, while recent US tax changes removed much of the case for a new takeover attempt.

Fri, 07 Nov, 2014